Page 1/1

Thomas Lingelbach

Intercell Plans to Achieve Turnaround in 2014

The Vienna-listed pharmaceutical company Intercell expects to return to the profit zone in 2014.

February 6, 2012

Intercell Looking for Private Equity Shareholder

According to Bloomberg, the Austrian pharmaceutical company negotiates with potential investors in order to strengthen the equity base.

September 27, 2011

Intercell Successfully Completes Vaccine Study in India

The Austrian biotech company achieved an important step in the licensure process of a vaccine for children.

September 16, 2011

Intercell Is Looking for Financial Investors

The ailing Austrian biotech company is in urgent need of cash. An acquisition, strategic partnerships and a capital increase are being evaluated.

July 19, 2011

Intercell: “We Will Stabilize Our Share Price”

The Austrian biotech company recorded a dramatic drop in its share price. The CEO remains optimistic and promises stabilization.

June 21, 2011

Intercell to Cut Jobs and Research Budget

The share price plunged by more than 30% after the Austrian pharmaceutical company had announced the termination of a vaccine study.

June 8, 2011

Intercell: Sale Is No Longer Ruled Out

The new CEO of the Austrian pharmaceutical company, Thomas Lingelbach intends to implement a new strategy for the company. A sale is possible.

May 11, 2011

Lingelbach New CEO for Intercell

Intercell announces new management structure: Thomas Lingelbach appointed new CEO; new Supervisory Board members proposed.

May 5, 2011